transperineal prostate biopsy
Recently Published Documents


TOTAL DOCUMENTS

201
(FIVE YEARS 101)

H-INDEX

24
(FIVE YEARS 4)

Author(s):  
Giacomo Maria Pirola ◽  
Marilena Gubbiotti ◽  
Emanuele Rubilotta ◽  
Daniele Castellani ◽  
Nicolò Trabacchin ◽  
...  

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Emily Cheng ◽  
Meenakshi Davuluri ◽  
Patrick J. Lewicki ◽  
Jim C. Hu ◽  
Spyridon P. Basourakos

2021 ◽  
Vol 33 ◽  
pp. S239
Author(s):  
A.E. Teixeira Dias ◽  
H.C.R Fortes ◽  
T.C Santos ◽  
B.L Marroig ◽  
C.e Melo ◽  
...  

2021 ◽  
Vol 8 ◽  
Author(s):  
Bi-Ming He ◽  
Rong-Bing Li ◽  
Hai-Feng Wang

Introduction: Transperineal prostate biopsy is as effective as the transrectal biopsy in detecting prostate cancer and has a lower risk of infection. However, concerning the procedural pain of the transperineal route, a higher level of anaesthesia is needed, which prevents this approach from being widely used. Although several methods of local anaesthesia to relieve pain during transperineal biopsy have been described, few well-designed trials have been conducted to assess the efficacy of local anaesthesia.Methods: This is a prospective, multicentre, randomised controlled study in men suspected of having prostate cancer and planning to undergo transperineal prostate biopsy. The aim of this trial is to determine whether the perineal nerve block and periprostatic block relieve pain to different extents in men undergoing transperineal biopsy. The main inclusion criteria are men aged between 18 and 80 years old, a prostate-specific antigen (PSA) level of 4–20 ng/ml, or/and suspicious rectal examination findings. A sample size of 190 participants, accounting for a 10% loss, is required. All participants will be randomly allocated at a ratio of 1:1 to the perineal nerve block (n = 95) and periprostatic block groups (n = 95). The primary outcome will be the level of the worst pain experienced during the transperineal prostate biopsy procedure, which will be measured by a numerical rating scale (NRS). The key secondary outcomes will include the pain severity score at 1, 6, and 24 h after prostate biopsy.Results: The primary outcome is the level of the worst pain experienced during the prostate biopsy procedure. The main secondary outcomes are as follows: (1) Post-biopsy pain severity score at 1, 6, and 24 h after the prostate biopsy; (2) Changes in blood pressure, heart rate and breathing rate during the biopsy procedure; (3) External manifestations of pain during biopsy; (4) Anaesthesia satisfaction; (5) The detection rate for clinically significant prostate cancer and any prostate cancer.Conclusion: Anaesthesia in PROstate biopsy Pain Obstruction Study (APROPOS) is randomised controlled trial aiming to determine the efficacy of the perineal nerve block in controlling pain in patients undergoing prostate biopsy via the transperineal approach.Clinical Trial Registration:www.ClinicalTrials.gov, identifier: NCT04501055.


Cancers ◽  
2021 ◽  
Vol 13 (19) ◽  
pp. 4833
Author(s):  
Andrea Fulco ◽  
Francesco Chiaradia ◽  
Luigi Ascalone ◽  
Vincenzo Andracchio ◽  
Antonio Greco ◽  
...  

The management of prostate biopsy in men with clinical suspicion of prostate cancer has changed in the last few years, especially with the introduction of imaging techniques, to overcome the low efficacy of risk stratification based on PSA levels. Here, we aimed to compare the diagnostic accuracy of multiparametric MRI with fusion ultrasound-guided prostate biopsy and standard biopsy, both performed through the transperineal route. To this end, we retrospectively analyzed 272 patients who underwent combined transperineal targeted and standard biopsy during the same session. The primary outcome was to compare the cancer detection rate between targeted and standard biopsy. The secondary outcome was to evaluate the added value of combined targeted and standard biopsy approach as compared to only targeted or standard biopsy. Results showed that a rate of 16.7% clinically significant tumors (International Society of Urological Pathology (ISUP) grade ≥ 2) would have been lost if only the standard biopsy had been used. The combined targeted and standard biopsy showed an added value of 10.3% and 9.9% in reducing the risk of prostate cancer missing after targeted or standard biopsy alone, respectively. The combined targeted and standard biopsy pathway is recommended to reduce the risk of missing clinically significant prostate cancer.


BJUI Compass ◽  
2021 ◽  
Author(s):  
Donnacha Hogan ◽  
Abbie Kanagarajah ◽  
Henry H. Yao ◽  
David Wetherell ◽  
Brendan Diaz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document